Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 4 · 80%High 0 · 0%

Aclidinium bromide vs tiotropium

Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease

It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).

1 finding from 1 review

Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.67 [0.17, 2.65]
2 studies · 729 participants
Very low

Aclidinium bromide vs placebo

Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease

Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 0.89 [0.7, 1.14]
10 studies · 5651 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with aclidinium alone (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.19 [0.79, 1.8]
3 studies · 2473 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs formoterol

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with formoterol (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.15 [0.82, 1.61]
5 studies · 3140 participants
Moderate

Fixed‐dose combination aclidinium/formoterol vs placebo

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes only
OR 1.12 [0.72, 1.74]
4 studies · 2527 participants
Moderate